The sodium iodide symporter (NIS) mediates iodide uptake into thyrocytes and is the molecular basis of thyroid radioiodine therapy. We previously have shown that NIS gene transfer into the F98 rat gliomas facilitated tumor imaging and increased survival by radioiodine. In this study, we show that: (1) 4) 188 ReO 4 , a potent b À emitter, is more efficient than 131 I to enhance the survival of rats bearing F98/hNIS gliomas. These studies demonstrate the importance of radiopharmaceutical selection, dose, and timing of treatment to optimize the therapeutic effectiveness of NIS-targeted radionuclide therapy following gene transfer into gliomas.
Introduction
The sodium iodide symporter (NIS) is a membrane glycoprotein that mediates iodide uptake in the thyroid gland and several extrathyroid tissues. NIS-mediated radioiodide uptake into thyroid epithelial cells is the molecular basis of thyroidal radioiodine therapy. The differential radioiodide accumulation in thyrocytes is further enhanced by the presence of iodide organification in thyroid tissues. Furthermore, iodide uptake/organification can be increased selectively in thyroid tissues by elevated serum thyrotropin levels. Consequently, most administered radioiodine is targeted to thyroid tissues, and radioiodine has been very effective in treating thyroid cancer, hyperthyroidism, and goiter.
Since the cloning of NIS, 1,2 many investigators have explored the ability of NIS gene transfer to facilitate targeted radioiodide therapy in nonthyroidal cancers. NIS gene transfer has been demonstrated to increase radioactive iodine uptake (RAIU) up to several hundredfold in a variety of cell types. [3] [4] [5] [6] In addition to allowing in vivo tumor imaging, [5] [6] [7] [8] [9] NIS gene transfer into tumor cells also renders them susceptible to being killed in vitro by 131 I. 4, 10, 11 However, lack of iodine organification in NIS-transduced tumors has raised concerns about the ultimate effectiveness of NIS-mediated radionuclide therapy for nonthyroidal malignancies, as an insufficient tumor radiation absorbed dose 8, 9 may result from short radionuclide retention time. Nevertheless, an NIStransduced prostatic tumor xenograft in mice was decreased in size by a single 3 mCi dose of 131 I injected intraperitoneally. 12 We hypothesized that NIS-mediated radionuclide therapy would be useful to treat tumors such as gliomas, which are currently limited by a narrow radiation therapeutic window. At least 55 Gy of external radiation is required to achieve tumor control; however, patients often developed normal brain tissue necrosis when more than 60 Gy of radiation is delivered solely by external radiation. [13] [14] [15] Although numerous strategies have been developed to increase the tumor-absorbed dose while minimizing radiation to normal brain tissues, thus far most of these attempts have proven unsatisfactory. Interstitial brachytherapy by physical placement of radionuclides in or near the tumor cannot differentiate microscopic tumors, from surrounding normal brain tissues, 16 as evidenced by a high incidence of symptomatic brain necrosis developing in patients treated with interstitial brachytherapy. 13, 17 Another strategy, radioimmunotherapy (RIT), has several limitations, including unwanted immunocomplex formation of radiolabeled antibody to nontumor tissues 18, 19 and the difficulty in delivering radiolabeled antibody across the blood-brain barrier (BBB). The differential distribution of radiolabeled antibody between tumors and normal tissues is often not satisfactory for targeted radionuclide therapy. 20 As shown in phase II-III clinical trials, locoregional administration of radiolabeled antibody into surgical cavities following tumor resection has modestly improved survival. [21] [22] [23] [24] However, many challenges exist to extend RIT to routine practice. For example, nonselective radiation to normal parenchyma, poor penetration of radiolabeled antibody into bulky tumors, and the complexity of the radiolabeling procedure remain as hurdles to the success of RIT in treating gliomas.
NIS-mediated radionuclide therapy has several features that make it an attractive approach for the treatment of patients with gliomas. Since glioma-targeted NIS gene transfer facilitates higher radionuclide accumulation in gliomas compared to the surrounding normal brain tissues, the differential radiation exposure between gliomas and normal brain tissues can be broadened. Furthermore, complex radiolabeling procedures are not required for NIS-mediated radionuclide therapy, since many NIS substrates have radioactive isotopes. Finally, the small sizes of NIS radioactive substrates should result in both increased penetration of the BBB and better diffusion capacity within the tumor compared to radiolabeled monoclonal antibodies. In our previous study, we showed that ex vivo NIS gene transfer to F98 rat glioma cells conferred a moderate survival benefit in 131 I-treated rats bearing intracerebral F98/hNIS gliomas. 5 In the present study, we show that the 
Results

I therapeutic effectiveness is dose-dependent and influenced by intervention time
To investigate whether 131 I therapeutic effectiveness is dose-dependent, several therapeutic trials of different 131 I doses were conducted. As shown in Table 1 , all treated rats appear to have improved survival compared to untreated rats. Statistical analysis using a two-sample t-test with unequal variance assumption showed that only the survival of rats treated with 16 mCi was significantly prolonged. In order to compare therapeutic effectiveness among different trials, the percentage of increased life span (%ILS) of treated rats with various doses of 131 I was calculated (see 'statistics' section in Materials and methods). There was a linear dosedependent increase of %ILS for administered doses of 131 I (R¼0.91). Similarly, the level of significance for improved survival, as indicated by P-value, increased with higher doses of 131 
I.
To investigate the effect of intervention time on therapeutic effectiveness, 16 mCi of 131 I was administered to rats bearing F98/hNIS glioma either 14 or 22 days post tumor implantation (DPI). Compared to the untreated rats, which had a mean survival time (MST) of Figure 3B) . A similar biological half-life was estimated by serial 123 I scintigraphy ( Figure 1 ). The MST of rats bearing RG2/hNIS gliomas treated with 16 mCi of 131 I on D14 (Table 3) was significantly different from the other groups at 5% level of significance (one-way ANOVA with Dunnett's test). There was no significant difference in the survival time among untreated rats bearing parental RG2 gliomas, untreated rats bearing RG2/LXSN gliomas, untreated rats bearing RG2/hNIS gliomas, and 131 I-treated rats bearing RG2/ LXSN gliomas. All rats bearing RG2-derived gliomas had approximately the same tumor sizes with similar histology when euthanized for moribund signs. Immunohistochemical staining against NIS revealed that I, compared to 131 I alone. As shown in Table 1 , all radioiodine-treated rats had prolonged survival times compared to untreated rats. However, only the MST of 131 I-and combined 125 I/ 131 I-treated rats bearing F98/ hNIS gliomas was significantly longer than that of the untreated group (5% level of significance, one-way ANOVA with Dunnett's test). Thus, with the same radioactivity administered on days 13 and 14 post tumor ReO 4 uptake up to 12 h post radionuclide injection ( Figure 3A) . Ex vivo tissue gamma counting showed that maximal 188 ReO 4 uptake in tumor occurred at 0.5 h post injection (Figure 3b) I was used in the study instead of 131 I, since both share the same pharmacokinetic properties and it is easier to quantify 
Discussion
This study extends our initial finding of modest therapeutic effectiveness of 131 I in prolonging survival of rats bearing F98/hNIS intracerebral gliomas. 5 The finding that 131 I therapeutic effectiveness in F98/hNIS gliomas was dose-dependent suggests that dose escalation could further improve the efficacy of NIS-targeted 131 I therapy. The validation of NIS-targeted 131 I therapy in another animal model further supports our hypothesis that NIS-mediated radionuclide therapy may be useful to circumvent the problem of a narrow therapeutic window intrinsic to brain tumor radiotherapy. The observation that 131 I-treated gliomas had reduced percentages of NISexpressing tumor cells, and that the extent of this reduction was more pronounced in rats with a longer survival time suggests a cytoreductive and/or a cytostatic effect of 131 ReO 4 were demonstrated in rats bearing intracerebral hNIS-transduced gliomas. These findings suggest that NIS-mediated radionuclide therapy may be further improved by the selection of an appropriate radionuclide or combination of multiple radionuclides based on the nature of the tumor.
The effective doses required to achieve tumor control vary among different tumors. For patients with high-grade gliomas, it is recommended that a total dose of 50-60 Gy external radiation be delivered postoperatively. 26 For patients with metastatic thyroid cancer, 131 I therapy is believed to be effective when tumor absorbed dose is greater than 80 Gy. 27 Assuming a uniform distribution of radioactivity in a 1 mm diameter spherical F98/hNIS glioma in a rat treated with 16 mCi of 131 I 14 DPI, we estimated the absorbed dose to be 26 Gy (1.6 Gy/mCi), using the MIRD method. 28 Thus, a higher dose of 131 I may be warranted to further increase the survival time.
A linear dose dependency of increased life span was observed without reaching a plateau (Table 1) , suggesting that the dose of maximal therapeutic efficacy may not have been reached. In addition, little evidence of radiotoxicity was observed in rats given the maximum (16 mCi) dose of 131 I. While some of the rats did suffer temporary weight loss (1-2%), they recovered their weight in 3-6 days following 131 I treatment. It is likely that the weight loss was due to radioiodine-induced gastritis, a common side effect in patients treated with 131 I. Gross and microscopic post-mortem examination, however, showed no difference in the appearance of the gastric mucosa in treated rats.
The fact that the percentage of NIS-expressing cells was greatly reduced in 131 I-treated rats bearing RG2/ hNIS gliomas, and that the degree of reduction correlated with the survival time of 131 I-treated rats suggest that 131 I had a cytoreduction effect on RG2/hNIS gliomas. By contrast, it is interesting to note that a reduction of NIS-expressing cells was not evident in 131 Itreated rats bearing F98/hNIS gliomas. Considering that rats bearing F98/hNIS gliomas had a prolonged survival by 131 I treatment, and that radioiodine uptake activity was diminished in 131 I-treated F98/hNIS gliomas (data not shown), it is most likely that 131 I had a cytostatic effect, rather than cytoreduction effect, on F98/hNIS gliomas.
The therapeutic effectiveness of 131 I administered 14 DPI (with undetectable tumor size) was greater than when administered 22 DPI (with tumor size of approximately 2 mm 3 ). This finding is in agreement with clinical observations that 131 I is more effective in treating microscopic, as opposed to macroscopic, metastatic thyroid cancer. 27, 29, 30 The maximal therapeutic effect of a radionuclide may occur when its emission spectrum matches the targeted tumor size. 31, 32 The calculated optimal tumor diameter for 131 I treatment is 2.6-5.0 mm. 31 In our study, the tumor diameters at 14 and 22 DPI are less than 2.6 mm. De Jong et al reported that therapy appeared more effective at treating smaller tumors as opposed to larger tumors, when tumor size is outside the optimal size range for 90 Y-octreotide. 32 
131
I therapy appeared more effective in treating rats bearing F98/hNIS gliomas (45-55% ILS) than RG2/hNIS gliomas (26% ILS). This was surprising, not only because the intrinsic radiosensitivity of RG2 gliomas is reportedly greater than that of F98 tumors, 33 but also because our calculated tumor-absorbed doses of RG2/hNIS gliomas were higher than those of F98/hNIS gliomas in rats treated with the same 131 I activity. However, RG2/hNIS glioma had a higher proliferation rate in vitro and in vivo, as suggested by an MST of 24 days for untreated RG2/ hNIS glioma-bearing rats compared to 35 days for untreated F98/hNIS gliomas-bearing rats in both group of rats following implantation of 1000 tumor cells. Consequently, the tumor sizes in rats bearing RG2/ hNIS gliomas would be predicted to be larger than those in rats bearing F98/hNIS gliomas at 14 DPI, when 131 I was administered. Thus, while greater radiosensitivity and higher tumor absorbed dose should lead to a greater extent of cytoreduction, they do not necessarily translate to better tumor control. Indeed, our data showed that the reduction in NIS-expressing cells by 131 I therapy was NIS-targeted radionuclide therapy in gliomas DHY Shen et al more pronounced in RG2/hNIS tumors than F98/hNIS tumors, yet rats bearing F98/hNIS gliomas had a higher %ILS. Thus, the efficacy of radionuclide therapy may be inadequate for tumors of high proliferative rate when viable tumor persists.
125 I emits ultra-short-ranged (generally less than 1 mm) Auger and Coster-Kronig electrons and produces high linear energy transfer (LET) cytotoxic effects, especially when 125 I is deposited in the proximity of the cell nucleus. [34] [35] [36] In small tumors, the majority of the 131 I b-decay energy deposition occurs outside the tumor, suggesting that 125 I may be more effective in such circumstances. 37 Conversely, in large tumors with an uneven distribution of radionuclide, 125 I may be inferior to 131 ReO 4 has a higher nonpenetrating emission energy spectrum and a higher dose rate. Assuming that all the b-decay energy is absorbed in targeted tumors, Dadachova et al estimated that the ratio of tumor-absorbed dose by 188 ReO 4 versus 131 I at the same level of radioactivity was about 4.5:1 using a murine xenograft model for breast cancer. 38 In contrast, our study showed a ratio of 2:3 using rats bearing NIS-transduced intracerebral glioma. In the xenografted breast cancer mouse model, comparable tumor uptake and retention time were observed resulting in slightly higher cumulative activity of 188 ReO 4 in NIS-transduced gliomas. 39, 40 The slower clearance of 125 I from blood circulation is anticipated by the large iodide pool in vivo that is contributed by the thyroid gland reservoir and entero-recirculation. 41 While 188 Re has been investigated for various clinical applications, such as endovascular brachytherapy or labeling various compounds to treat cancer and to palliate bone pain, 42, 43 this is the first report to examine the therapeutic effectiveness of 188 ReO 4 for NIS-expressing tumors. Assuming the tumor diameter was approximately about 1 mm at 14 DPI, the tumor-absorbed dose for rats carrying F98/hNIS gliomas treated with 8 mCi of 188 ReO 4 appeared to be more efficient than 131 I in prolonging the survival of rats bearing F98/hNIS gliomas. This is likely explained by the greater energy release in a short time interval by 188 Re compared to 131 I, 1096 versus 24 keV/day, respectively. 44 Other benefits of using 188 ReO 4 , instead of 131 I, to treat nonthyroidal malignancies include the potential for less damage to the thyroid gland given the lack of 188 ReO 4 organification, 38 and superior gamma scintigraphy qualities. Recently, NIS-mediated uptake of 211 At, an a emitter with high LET, was demonstrated. 45, 46 Thus, 211 At may potentially be useful for NIS-targeted radionuclide therapy.
Materials and methods
Establishment of rat models bearing intracerebral human NIS expressing F98 or RG2 gliomas
The protocol to establish a rat model bearing human NIS (hNIS) expressing F98 gliomas was described previously. 5 A DNA construct containing full-length hNIS cDNA driven by the Moloney murine leukemia virus long terminal repeat (LTR) promoter and a selection marker Neo r driven by SV40 promoter (referred to as L-hNIS-SN) was created and transfected into PA317 retroviral packaging cells. PA317 cells carrying L-hNIS-SN were selected by geneticin (G418) treatment (Gibco BRL, Grand Island, NY, USA), and stable clones were selected that produce the recombinant retrovirus carrying hNIS. As a control, we produced a recombinant retrovirus carrying empty vector (L-X-SN). F98 or RG2 rat glioma cells were infected with recombinant retrovirus carrying L-hNIS-SN and selected by G418. Clonal cell lines with stable NIS expression (referred to as F98/ hNIS and RG2/hNIS, respectively) were isolated and expanded. Colonies showing the highest in vitro 125 I uptake (B40 times in F98/hNIS and B120 times in RG2/ hNIS, as compared to the non-NIS transduced controls) were used for further experiments. The control (F98/ LXSN or RG2/LXSN) indicated respective glioma cells carrying the empty vector, L-X-SN, which was generated in a similar procedure.
Male Fisher rats (Harlan Inc., Indianapolis, IN, USA) weighing B200 g were stereotactically implanted with tumor cells, as described elsewhere. 47, 48 Following induction of anesthesia with an intraperitoneal (i.p.) dose of 20 mg ketamine/120 mg xylazine mixture per kilogram of body weight (Fort Dodge, Fort Dodge, IA, USA) in 0.2 ml volume, 1000 tumor cells in 10 l of serum-free DMEM containing 1.4% agarose were injected over 10-15 s into the right hemisphere using a stereotactic instrument. At 1 week prior to the radionuclide therapy, imaging studies, or radionuclide biodistribution studies, rats were placed on a 1 ppm thyroxin (T4)-supplemented diet (Harlan Teklad, Madison, WI, USA). Tumor-bearing rats were imaged under anesthesia by i.p. injection of the ketamine/xylazine mixture. A dual head gamma camera (Picker Prism 2000XP Baseline V8.5A, gantry-fixed, PCD-and SPECT-capable, Marconi Medical Systems, Cleveland, OH, USA) equipped with a pinhole collimator and a low-energy ultra-high-resolution parallel hole collimator (LEUHR), respectively, on each head of the gamma camera was used for imaging acquisition so that a focal brain view and a whole body view were obtained simultaneously. To determine the average uptake value of tumor (%ID per gram of tumor, ie %ID/g), tumor-bearing rats were first intravenously (i.v.) injected with 2% Evans Blue (Sigma, St Louis, MO, USA) in 1 ml normal saline to stain the BBB breakdown site, localizing the brain tumor region. The tumor weight was determined by weighing the Evans blue-stained tumor excised from the corresponding rat brain after imaging was completed. The tumor radionuclide uptake was calculated and expressed as %ID/g. Biological half-life (T 1/2 ) of radionuclide in tumor was estimated based on the time activity curve (TAC) generated by plotting the tumor ROI count rates or %ID/g versus time.
Ex vivo measurement of in vivo 125 I uptake in tumor and other tissues 125 I biodistribution studies were performed using groups of tumor-bearing rats injected i.p. with carrier-free 125 I (Amersham Pharmacia Biotech, Piscataway, NJ, USA) at 0.15 mCi per gram of body weight in 0.5 ml of normal saline. Total administered radioactivity counts were calculated by subtracting the radioactivity of the postinjected syringe from that of the preinjected one measured by a g-counter (Packard, GMI, Inc., MN, USA) for each animal injection. Prior to the euthanization of animals, 2% Evans Blue in 1 ml normal saline was injected intravenously to localize the brain tumor region. Groups of rats (three rats per group) were killed by CO 2 asphyxia at the indicated time post 125 I injection, and 1-ml blood, thyroid gland, stomach, salivary gland, lung, liver and spleen, as well as the brain were collected. Next, the brain was cut into 2-mm coronal sections with a rat brain slicer (Zivic-Miller Laboratories, Inc., Allison Park, PA, USA). From each section, the Evans bluestained tissue and a piece of unstained brain tissue were excised, weighed, and measured for their radioactivity by a g-counter. After normalization for total administered radioactivity, the average uptake value of radioiodine in tissues of interest was determined as %ID/g. Re radioactivity using its g energy window (155720 KeV). After 1 week, when 188 Re radioactivity had decayed, the tissues were counted for 125 I radioactivity in its g energy window (35710 KeV). The total administered radioactivity for each radionuclide was measured in counts by subtracting the radioactivity of the postinjected syringe from that of the corresponding preinjected one for each animal in the study. The average uptake value (%ID/g) of respective radionuclides in tumors and other tissues at different time points was determined. Rhenium generator at one time, the treatment experiment was divided into two batches.
RG2 glioma-bearing rats were also included to investigate the resulting survival times by strategies of NIS gene transfer alone (N¼7), LXSN vector transfer (N¼7) alone, 16-mCi 131 I treatment of nontransduced tumors (N¼7), or NIS gene transfer followed by 16-mCi 131 I treatment (N¼10) in comparison with the control group, that is wild-type RG2 (N¼5).
The survival time of each animal was determined as previously described. 5 Rats were euthanized when they displayed moribund signs, which consisted of sustained weight loss, ataxia, and periorbital hemorrhage. Survival times were determined as the day of tumor implantation to the day of euthanization plus 1 day. The observers were not blinded when killing the rats. All tumorbearing animals were grossly examined for any abnormality of their viscera in necropsy. The intracerebral tumors were confirmed by routine histopathological examination of hematoxylin and eosin-stained tissues sections, unless they were used for ex vivo measurement of 125 I uptake.
Anti-hNIS immunohistochemical (IHC) staining
IHC staining was performed as previously described with some modifications. Briefly, tissue sections were incubated with hNIS polyclonal antibody #331 (1:1,000 dilution) at room temperature for 1 h, and then incubated with biotinylated goat anti-rabbit IgG (1:200 dilution, Vector Lab. Inc., Burlingame, CA, USA) for 20 min. To semiquantify the hNIS IHC signal, the following 0 to 4 þ system was used to estimate the percentage of NIS-expressing tumor cells: 0 þ 0, 1 þ 25, 2 þ 50, 3 þ 75, and 4 þ 100%.
Statistics
The average uptake values of radionuclides in tissues of interest were expressed as mean7s.d. Survival time among different experimental groups was also expressed as mean7s.d. and then MSTs were compared using a two-tailed, unpaired t-test with assumption of unequal variance. When multiple comparisons were made, the difference of MST for one indicated group from the others was determined by one-way ANOVA with Dunnett's test. The %ILS was determined as the ratio of the difference between the MST of experimental and untreated control groups and the MST of untreated control group multiplied by 100%. Regression analysis was performed to test the correlation between therapeutic 131 I dose and resulting %ILS and between hNIS IHC grading and survival time. A P-value o0.05 was considered statistically significant. All statistical analyses were performed using SAS JMP Version 4 (SAS Institute, Cary, NC, USA).
